January 2025 was a month of important events in global pharmacology. From new drugs to innovative therapies, we look at the main news that will affect the future of medicine.
Biogen, a US company, and Eisai, a Japanese company, have received FDA approval for Lecanemab, the first drug to significantly slow the progression of early-stage Alzheimer’s disease. Clinical trials have shown that the drug could be a breakthrough in the treatment of the disease.
Vertex Pharmaceuticals announced successful results from a Phase 3 clinical trial of its VX-880 therapy, an innovative treatment that uses stem cells to restore insulin production in patients with type 1 diabetes. The drug has already received conditional approval in the EU and the US.
GSK and WHO have launched a new vaccine, R21/Matrix-M, which has been shown to be over 80% effective in preventing malaria in children. The vaccine has already begun to be introduced in African countries, where malaria remains a leading cause of death.
Swiss company Roche has introduced a new targeted drug, RGX-202, which shows promising results in the treatment of late-stage pancreatic cancer. The drug blocks key survival mechanisms of cancer cells, which allows to slow down the progression of the disease.
Moderna has announced the start of clinical trials of a universal mRNA flu vaccine. The vaccine is expected to provide protection against all known strains of the flu virus, using technology similar to the COVID-19 vaccine.
Discussions continue in Europe and the US about the use of CRISPR technology to edit the human genome. In January 2025, the first CRISPR drug was approved to treat hereditary blood diseases, sparking new controversy over the regulatory and ethical aspects of genetic engineering.
Large pharmaceutical companies such as Pfizer and Novartis have announced expansion of programs to develop personalized medicines based on patients’ genetic data, an approach that is becoming one of the key directions in modern pharmacology.
The EU has adopted new standards to reduce the carbon footprint of pharmaceutical manufacturing, with companies such as AstraZeneca and Sanofi announcing their transition to green technologies in line with sustainable development.
January 2025 showed that global pharmacology continues to develop rapidly. Innovative drugs, new vaccines and personalized medicine are becoming the main directions that are changing the future of healthcare. At the same time, attention is growing to the environmental aspects of production, making the pharmaceutical industry more responsible and sustainable.
Follow the news in the world of medicine – the future is just around the corner!
In the face of a global environmental crisis, modern waste processing technologies play a key role in creating a sustainable future. One such technology is thermal depolymerization.
Environmentally friendly processing of mixed household waste is made possible by modern equipment. The MSW processing complex is based on high-tech installations that ensure efficiency and minimal environmental impact.
The problem of effective management of municipal solid waste (MSW) is becoming increasingly urgent. An innovative project of an energy complex for processing mixed waste offers a modern solution that not only minimizes its impact on the environment, but also generates valuable commodity resources.
Copyright © 2023 INSTITUTE OF NANOTECHNOLOGY AND ORGANIC PRODUCTS “AVELIFE”
